Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins

被引:136
作者
Yamada, M
ORegan, E
Brown, R
Karran, P
机构
[1] IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND
[2] CRC,BEATSON LABS,DEPT MED ONCOL,GLASGOW G61 1BD,LANARK,SCOTLAND
关键词
D O I
10.1093/nar/25.3.491
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The antitumor agent cis-diamminedichtoroplatinum(II) (cisplatin) introduces cytotoxic DNA damage predominantly in the form of intrastrand crosslinks between adjacent purines. Binding assays using a series of duplex oligonucleotides containing a single 1,2 diguanyl intrastrand crosslink indicate that human cell extracts contain factors that preferentially recognise this type of damage when the complementary strand contains T opposite the 3', and C opposite the 5' guanine in the crosslink, Under the conditions of the band-shift assay used, little binding is observed if the positions of the T and C are reversed in the complementary strand, Similarly, duplexes containing CC or TT opposite the crosslink are recognised relatively poorly The binding activity is absent from extracts of the colorectal carcinoma cell lines LoVo and DLD-1 in which the hMutS alpha mismatch recognition complex is inactivated by mutation. Extensively purified human hMutS alpha exhibits the same substrate preference and binds to the mismatched platinated DNA at least as well as to an identical unplatinated duplex containing a single G . T mismatch, It is likely, therefore, that human mismatch repair may be triggered by 1,2 diguanyl intrastrand crosslinks that have undergone replicative bypass.
引用
收藏
页码:491 / 495
页数:5
相关论文
共 33 条
[1]  
Aebi S, 1996, CANCER RES, V56, P3087
[2]  
ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35
[3]  
Anthoney DA, 1996, CANCER RES, V56, P1374
[4]   A MISMATCH RECOGNITION DEFECT IN COLON-CARCINOMA CONFERS DNA MICROSATELLITE INSTABILITY AND A MUTATOR PHENOTYPE [J].
AQUILINA, G ;
HESS, P ;
BRANCH, P ;
MACGEOCH, C ;
CASCIANO, I ;
KARRAN, P ;
BIGNAMI, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (19) :8905-8909
[5]  
BRANCH P, 1995, CANCER RES, V55, P2304
[6]  
CHU G, 1994, J BIOL CHEM, V269, P787
[7]  
CLUGSTON CK, 1992, CANCER RES, V52, P6375
[8]   CHARACTERIZATION OF A DNA DAMAGE-RECOGNITION PROTEIN FROM MAMMALIAN-CELLS THAT BINDS SPECIFICALLY TO INTRASTRAND D(GPG) AND D(APG) DNA ADDUCTS OF THE ANTICANCER DRUG CISPLATIN [J].
DONAHUE, BA ;
AUGOT, M ;
BELLON, SF ;
TREIBER, DK ;
TONEY, JH ;
LIPPARD, SJ ;
ESSIGMANN, JM .
BIOCHEMISTRY, 1990, 29 (24) :5872-5880
[9]   ISOLATION OF AN HMSH2-P160 HETERODIMER THAT RESTORES DNA MISMATCH REPAIR TO TUMOR-CELLS [J].
DRUMMOND, JT ;
LI, GM ;
LONGLEY, MJ ;
MODRICH, P .
SCIENCE, 1995, 268 (5219) :1909-1912
[10]   Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line [J].
Drummond, JT ;
Anthoney, A ;
Brown, R ;
Modrich, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (33) :19645-19648